INTRODUCTION
============

Involuntary motor activity often follows lesions of motor pathways in the central nervous system. Traditionally spasticity has been assessed by the clinical signs \[[@b1-arm-2019-43-5-555]\]. However a large percentage of patients report involuntary motor activity without the sign of spasticity \[[@b2-arm-2019-43-5-555],[@b3-arm-2019-43-5-555]\]. The definition of spasticity has therefore been suggested to include all involuntary muscle activity following an upper motor neuron lesion \[[@b4-arm-2019-43-5-555]\]. Spasticity is considered problematic if it is perceived by the individual or caregivers "as hindering body function, activities and/or participation" \[[@b5-arm-2019-43-5-555]\].

Spasticity affects a majority of persons with spinal cord injuries (SCI) \[[@b2-arm-2019-43-5-555],[@b6-arm-2019-43-5-555]\], develops during the first months after the injury and persists over a long time after the injury. Intrathecal baclofen administration (ITB) is an effective and safe treatment for severe leg spasticity up to 9 years \[[@b7-arm-2019-43-5-555]-[@b10-arm-2019-43-5-555]\]. The dose usually stabilizes after 1--2 years. In contrast to SCI, multiple sclerosis (MS) is usually a progressive disease and the progressive stage invariably includes spastic paraparesis \[[@b11-arm-2019-43-5-555]\]. This spasticity also responds well to ITB \[[@b7-arm-2019-43-5-555],[@b12-arm-2019-43-5-555]\]. Treatment exceeding 7 years improves the Ashworth Scale as well as the Barthel Index \[[@b13-arm-2019-43-5-555]\]. Tolerance to ITB after SCI was reported in up to 22% of patients within 3 years \[[@b14-arm-2019-43-5-555]\] while another study with a longer follow-up failed to show the need for increased dosage in patients with SCI and MS \[[@b15-arm-2019-43-5-555]\]. However, in the latter study the dose changes were estimated by complex statistics and involved a small number of patients with a longer follow-up.

The present study sought to investigate changes in ITB dosage after 7 years of treatment and beyond, and compared the dose evolution in patients with a stable neurological condition (SCI), and in patients with a progressive neurological condition (MS). Since dosages vary considerably between patients, the present study investigated the changes in each individual patient.

MATERIALS AND METHODS
=====================

A retrospective chart review was approved by the Regionala Etikprovningsnamnden i Goteborg, M2 (No. 375-16). Patients were selected if they were treated with ITB over a period of at least 7 years for severe leg spasticity (n=49).

All the patients exhibited severe leg and occasional trunk spasticity and failed to respond effectively to oral baclofen, or showed severe side effects. Indications for ITB treatment include a significantly decreased score on the Ashworth Scale following an intrathecal test dose of baclofen. ITB was initiated in the first patient during 1989 and in the last patient 2008. Pump implantation followed standard procedures with a catheter tip positioned at the low thoracic level. The pump models used were Medtronic SynchroMed EL until 2002 followed by SynchroMed II. The pumps were usually replaced every 5th or 7th year, respectively.

The effect on spasticity was estimated by discussion among patients and their health providers including nurse(s) and physician(s), usually 4--10 times per year, in order to reduce leg spasticity and avoid any increase in leg/trunk weakness. All the physicians were neurologists or experienced residents in neurology. They were all experienced in programming a baclofen pump. If the patient described spasticity during a particular time of the day, the pump was switched to flexdose and programmed to administer a higher dosage during this time. The medical records were reviewed for pump system failures or factors that aggravated spasticity. In the presence of any such problems, the follow-up of dosage changes was terminated 1 year before the event.

Statistics
----------

The dosage one year after the start of ITB was compared with the dosage after 7 and 10 years in each patient. The mean percentage change in SCI patients was compared with that of the MS patients. The significance of the difference was tested by t-test. The t-test, Mann-Whitney U-test and univariate analysis of variance were calculated using SPSS version 22.0 (IBM, Armonk, NY, USA).

RESULTS
=======

Of the 49 patients with a follow-up of 7 years or longer, eight presented with catheter/pump failure, which aggravated spasticity or mental problems within 7 years after starting pump treatment, which excluded them from the follow-up ([Table 1](#t1-arm-2019-43-5-555){ref-type="table"}). The most common factor was catheter failure and catheter tip dislodgement.

Of the remaining 41 patients, 19 had SCI and 22 MS. The 19 SCI patients included 15 cervical and 4 thoracic cases. The degree of spinal lesion was estimated by the American Spinal Cord Injury Association impairment score (AIS)---A (n=6), B (n=5), C (n=3), and D (n=3). The disability of patients with MS was estimated by the Expanded Disability Status Scale (EDSS) and ranged from 6.5 to 9.0 at the start of the pump treatment. After 7 years, the EDSS scores increased in 17 of the 21 MS patients ([Table 2](#t2-arm-2019-43-5-555){ref-type="table"}). In the last follow-up, all the MS patients except one showed severe disability (EDSS 8--9.5).

During the first year after implantation, the dosage was steadily increased to elicit a sustained effect on spasticity. Seven of the MS patients were treated with a dose that varied during the day or night (flex dose) and this regimen was introduced within the first year. The remainder of the patients were treated with the same dose throughout the day and night (continuous). One year after the start of ITB, the SCI patients ([Table 3](#t3-arm-2019-43-5-555){ref-type="table"}) needed a median daily dose of 260 mg/24 hr (range, 30--725 mg). The MS patients ([Table 2](#t2-arm-2019-43-5-555){ref-type="table"}) required a lower dose, with a median dosage of 112 mg/24 hr (range, 66--420 mg). The mean dosage for the SCI patients was 257 mg/24 hr (95% confidence interval \[CI\], 189--325) and for the MS patients 158 mg/24 hr (95% CI, 113--204), and the difference was significant (t-test p=0.02).

Seven and 10 years after initiating the pump treatment, the dosage was only slightly increased in the SCI group ([Fig. 1](#f1-arm-2019-43-5-555){ref-type="fig"}), to median dosages 260 mg/24 hr (n=19) and 276 mg/24 hr (n=19). In contrast, the dosage was considerably increased in the MS group, and the median dosages were 175 mg/24 hr after 7 years (n=22), and 190 mg/24 hr after 10 years (n=18). The dosage in each individual patient of the SCI group ([Fig. 2](#f2-arm-2019-43-5-555){ref-type="fig"}) was increased to a mean of 113% (95% CI, 99--128) after 7 years and to a mean of 121% (95% CI, 104--139) after 10 years compared with the 1-year dosage ([Fig. 3](#f3-arm-2019-43-5-555){ref-type="fig"}). By contrast, in the MS group the corresponding increases after 7 years were 158% (95% CI, 131--184) and after 10 years 194% (95% CI, 153--236). A t-test comparing the percentage change in the SCI and MS groups showed a significant difference between the two groups (7 years, p=0.006 and 10 years, p=0.004). The 7 MS patients with flex dose showed a mean increase to 166% (95% CI, 146--186) after 7 years compared with 153% (95% CI, 116--191) in the 15 MS patients with a continuous daily dose. Both the SCI and MS groups showed low levels of spasticity after 7 and 10 years, reflected by low Ashworth scores (0--1).

A univariate analysis of the changes after 7 years included factors such as gender, patient type (SCI/MS), flex dose and pump change before year 7, and the covariate age at pump initiation. We found that patient type was the only significant factor (p=0.048).

DISCUSSION
==========

The results indicate that the demand for intrathecal baclofen from 1 year after pump start was constant in patients with SCI while increasing in progressive MS disease. At the follow-up after 7 to 10 years, the dosages in MS patients approached those found in the SCI patients. The dose of intrathecal baclofen required for an optimal effect in leg spasticity varied considerably between patients in both the SCI and MS groups, although the mean dosage 1 year after pump start was considerably higher in the SCI patients in accordance with previous studies \[[@b10-arm-2019-43-5-555]\]. The dosage in the SCI patients appeared not to increase significantly at least up to 10 years after implantation assuming that the pump system did not malfunction. By contrast, the MS patients needed successively higher dosages despite increased trunk weakness in a few MS patients preventing an increase in dosage. A similar difference between MS and non-MS patients was found in a 2- to 3-year follow-up \[[@b16-arm-2019-43-5-555]\]. In the present study, the increase of EDSS score reflected the progressive nature of the disease in MS patients. A Norwegian study reported unchanged dosage after 10 years, however, the four patients showed no increase in their EDSS score \[[@b12-arm-2019-43-5-555]\]. Constant dosages were also found in a study followup over 4 to 8 years \[[@b17-arm-2019-43-5-555]\] among progressive and nonprogressive patients, although the changes in EDSS were not reported. In another study with a longer follow-up, no differences were found between MS and SCI patients \[[@b15-arm-2019-43-5-555]\]. In the latter study, all the dosages were included (including patients followed over a shorter time period), and the trend for long-term dosage changes was calculated using a mixed linear effect method. In that study, 30 patients were treated with a pump for 10 years, however, the number of MS and SCI patients was not indicated. Further, the study failed to mention the EDSS of patients who were followed for 7 or 10 years. It is therefore, difficult to appraise the results in that study. The univariate analysis in the present study showed that flex dose or a pump change did not significantly affect the 7-year dosage change. We believe that the increased baclofen dosage in the present study reflects the progressive course of disease in MS and the continuing deterioration of the descending pathways.

A major limitation of the present study relates to the perceived spasticity by the patients or their caregivers, and failed to include a systematic evaluation of the effects of spasticity on major daily activities. The perceived spasticity is strongly dependent on the mental status of the patients \[[@b18-arm-2019-43-5-555]\]. The mental status is commonly altered in MS. The increased dosages detected in the MS patients could also be attributed to pump system malfunction, however, such a systemic failure should also have affected SCI patients. Because of the constant baclofen dosage in SCI patients, a large dosage increase in this patient group should warrant an investigation into a possible pump failure, spasticity trigger factors or progressive spinal disease.
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###### 

Patients omitted from follow-up due to pump system malfunction or other factors within 7 years after baclofen pump initiation

  Sex   Illness   Age trauma/debut MS (yr)   AIS/type MS   Level   Pump start year after trauma/debut   Problem                         Year after pump start
  ----- --------- -------------------------- ------------- ------- ------------------------------------ ------------------------------- -----------------------
  F     SCI       17                         C             C6      2                                    Mental illness, pressure sore   7
  M     SCI       41                         C             C4      3                                    Pump infection                  7
  M     SCI       18                         A             C4      16                                   Pump                            7
  M     SCI       20                         C             T7      8                                    Catheter                        3
  M     MS        20                         SPMS          \-      20                                   Catheter                        5
  F     MS        33                         SPMS          \-      19                                   Catheter                        3
  F     MS        19                         SPMS          \-      18                                   Catheter                        3
  M     MS        23                         SPMS          \-      16                                   Catheter                        5

MS, multiple sclerosis; AIS, American Spinal Injury Association impairment scale; SCI, spinal cord injury; SPMS, secondary progressive multiple sclerosis.

###### 

Patients with multiple sclerosis

  Sex   MS debut age (yr)   Progress (yr)   Pump disease (yr)   EDSS pump start   Dose year 1   Dose year 7                                               \% change dose   EDSS year seven   Dose pattern   Reason for change   Pump changed year
  ----- ------------------- --------------- ------------------- ----------------- ------------- --------------------------------------------------------- ---------------- ----------------- -------------- ------------------- -------------------
  F     44                  PP              6                   8.0               420           580                                                       138              8.0               Flex           Stiff evening       8
  F     21                  4               16                  7.0               220           346                                                       157              8.0               Flex           Spasms              8
  F     22                  11              21                  7.0               77            165                                                       214              7.5               Flex           Stiff at night      5
  M     42                  PP              30                  8.0               120           300^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   250              9.5               Cont           Stiffness           7
  F     36                  6               19                  8.0               108           110                                                       102              8.5               Cont           Stiffness           5,10,18
  F     35                  PP              16                  9.0               130           330                                                       254              9.5               Cont           Stiffness           8
  M     18                  10              19                  6.5               70            116                                                       166              7.5               Flex           Stiff at night      6,16
  M     25                  SP              31                  7.0               78            121^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   155              7.5               Cont           Spasticity          End year 7
  F     18                  SP              36                  9.0               80            91^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^    114              9.0               Cont           Spasticity          End year 7
  M     21                  2               11                  9.0               139           399                                                       287              9.0               Cont           Flexor spasm        8
  F     28                  SP              28                  8.0               66            85^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^    129              9.0               Cont           Stiff morning       7
  F     16                  SP              29                  7.0               89            170                                                       191              8.0               Flex           Spasms at night     5,12
  F     29                  9               30                  7.0               94            105                                                       112              9.0               Cont           Stiffness           8
  M     30                  SP              19                  7.5               259           400                                                       154              8.0               Flex           Spasms morning      3,12
  M     30                  3               16                  8.0               385           473                                                       123              9.0               Cont           Rigidity            8
  M     19                  10              28                  8.0               115           165                                                       143              9.0               Flex           Spasms              5
  F     49                  PP              2                   8.0               77            88^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^    114              9.0               Cont           Spasticity          7
  F     41                  SP              14                  8.0               100           120^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   120              8.5               Cont           Spasticity          7
  F     30                  SP              27                  8.0               200           180^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   90               8.0               Cont           Spasticity          7
  M     32                  PP              19                  8.5               190           200^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   105              9.0               Cont           Spasticity          7
  F     34                  SP              26                  8.5               375           250^[a)](#tfn1-arm-2019-43-5-555){ref-type="table-fn"}^   67               9.5               Cont           Spasticity          7
  F     26                  SP              15                  8.0               90            250                                                       278              9.0               Cont           Spasticity          5

MS, multiple sclerosis; EDSS, Expanded Disability Status Scale; PP, primary progressive MS; SP, secondary progressive MS with unknown progression year; Flex, variable dose during 24 hours started within the first year; Cont, continuous dose (the same dose during 24 hours).

Dosage before the pump change.

###### 

Patients with spinal cord injury

  Sex   Trauma age (yr)   Level   AIS   Walker   Pump year after trauma   Dose year 1   Dose year 7                                               \% change   Dose pattern   Reason for change   Pump changed year
  ----- ----------------- ------- ----- -------- ------------------------ ------------- --------------------------------------------------------- ----------- -------------- ------------------- -------------------
  M     54                C3      A     No       0.25                     256           260^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   102         Cont           Spasticity          7
  M     18                C4      A     No       1                        264           360                                                       136         Cont           Spasticity          4, 10, 15, 22
  M     28                C4      A     No       6                        260           300^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   115         Cont           Spasticity          7
  F     45                C5      A     No       2                        172           252                                                       147         Cont           Spasticity          8
  M     17                C5      A     No       15                       125           120                                                       96          Cont           Spasticity          511
  M     20                C5      A     No       4                        168           330                                                       196         Cont           Spasticity          5, 11
  M     23                C8      A     No       8                        372           352                                                       95          Cont           Spasticity          6, 13
  F     41                C7      B     No       9                        360           336                                                       93          Cont           Spasticity          5, 10, 15, 22
  F     47                C7      B     No       1                        167           168^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   101         Cont           Spasticity          7, 12
  F     27                C7      B     No       37                       383           550^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   144         Cont           Spasticity          7, 12
  M     48                T4      B     No       2                        264           240                                                       91          Cont           Spasticity          5, 10, 17
  M     23                T7      B     No       8                        276           253^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   92          Cont           Spasticity          7
  M     49                C3      C     Yes      11                       75            75                                                        100         Cont           Spasticity          8
  M     59                C4      C     No       0.25                     725           750^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   103         Cont           Spasticity          7
  M     61                C5      C     No       0.25                     288           350                                                       122         Cont           Spasticity          8
  M     26                T11     C     No       1                        361           396                                                       110         Cont           Spasticity          5, 13
  M     51                C5      D     Yes      5                        30            48                                                        160         Cont           Spasticity          5, 10, 17
  M     62                C7      D     Yes      2                        170           112^[a)](#tfn2-arm-2019-43-5-555){ref-type="table-fn"}^   66          Cont           Spasticity          7
  F     56                T1      D     No       4                        168           143                                                       85          Cont           Spasticity          8

AIS, American Spinal Injury Association impairment scale; Cont, continuous dose (the same dose during 24 hours).

Dose before the pump change.
